117323-81-6

Basic information

• Product Name: 2-(2-Morpholin-4-yl-benzylsulfanyl)-1-pyridin-2-yl-1,4,5,6-tetrahydro-cyclopentaimidazole
• Synonyms: 2-(2-Morpholin-4-yl-benzylsulfanyl)-1-pyridin-2-yl-1,4,5,6-tetrahydro-cyclopentaimidazole
• CAS NO: 117323-81-6
• Molecular Weight: 392.525
• Mol File: 117323-81-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2-(2-Morpholin-4-yl-benzylsulfanyl)-1-pyridin-2-yl-1,4,5,6-tetrahydro-cyclopentaimidazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-Morpholin-4-yl-benzylsulfanyl)-1-pyridin-2-yl-1,4,5,6-tetrahydro-cyclopentaimidazole(117323-81-6)
• EPA Substance Registry System: 2-(2-Morpholin-4-yl-benzylsulfanyl)-1-pyridin-2-yl-1,4,5,6-tetrahydro-cyclopentaimidazole(117323-81-6)

Safety Data

• Hazardous Substances Data: 117323-81-6(Hazardous Substances Data)

Upstream product

• 110405-99-7 2-morpholinobenzyl chloride 
• 117296-95-4 6a-Hydroxy-1-pyridin-2-yl-hexahydro-cyclopentaimidazole-2-thione 
• 223560-37-0 methyl 2-morpholinobenzoate 
• 465514-33-4 (2-morpholin-4-ylphenyl)methanol 
• 394-35-4 methyl 2-fluorobenzoate 

Relevant articles and documents

2-[(2-Aminobenzyl)sulfinyl]-1-(2-pyridyl)-1,4,5,6- tetrahydrocyclopent[d]imidazoles as a novel class of gastric H+/K+-ATPase inhibitors

Substituted 2-sulfinylimidazoles were synthesized and investigated as potential inhibitors of gastric H+/K+-ATPase. The 4,5-unsubstituted imidazole series 6-11 and the 1,4,5,6-tetrahydrocyclopent[d]imidazole series 12 were found to be potent inhibitors of the acid secretory enzyme H+/K+- ATPase. Structure-activity relationships indicate that the substitution of 2- pyridyl groups at the 1-position of the imidazole moiety combined with (2- aminobenzyl)sulfinyl groups at the 2-position leads to highly active compounds with a favorable chemical stability. Other substitution patterns in the imidazole moiety result in reducing biological activities. 2-[(2- Aminobenzyl)sulfinyl]-1-[2-(3-methylpyridyl)]-1,4,5,6- tetrahydrocyclopent[d]imidazole (12h, T-776) was selected for further development as a potential clinical candidate. Extensive study on the acid degradation of 12h indicates a mechanism of action different from that of omeprazole, the first H+/K+-ATPase inhibitor introduced to the market.